Alpha¹ by KaimenConfidential

Kaimen Rigor review

Omalizumab for the Treatment of Multiple Food Allergies.

Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS

DOI: 10.1056/NEJMoa2312382
Record issued: 2026-08-16
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/5145b307-3da0-47c7-a4e7-ca7c36e126dd is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is the ability to consume a threshold dose of food protein without dose-limiting symptoms during a food challenge, which is a surrogate for protection against accidental exposure. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data showing IgE suppression) nor cite validated evidence linking this surrogate to a hard clinical outcome such as reduced anaphylaxis or improved quality of life. The surrogate is a mechanistic proxy for clinical benefit.
“The primary end point was ingestion of peanut protein in a single dose of 600 mg or more without dose-limiting symptoms.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is reported as 67% of omalizumab-treated participants meeting the threshold versus 7% on placebo, but the threshold (600 mg peanut protein) is a surrogate and the clinical meaningfulness is not anchored to a validated minimal clinically important difference or a hard outcome. The paper states the effect 'likely exceed[s] those that would be needed for accidental exposure' but does not provide a validated anchor for clinical significance.
“These levels of protection are likely to exceed those that would be needed for the amounts of food that are typically encountered during accidental exposure”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized controlled trial with rigorous design, clear reporting of methods and results, and appropriate statistical analysis. The main weaknesses are minor reporting gaps: lack of detailed data sharing mechanism, unspecified statistical software, and incomplete demographic detail. The paper is methodologically sound and transparent overall.

Both reviewers agreed on study type (interventional) and on all dimension statuses. The synthesis merged their evidence, noting minor divergences in sub-criteria ratings (e.g., demographics, limitations addressed) but these did not change the overall statuses. The statistics verification checked 4 tests, all consistent; the citation check found no retracted or missing references; the reproducibility check found the one link live.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Primary endpoint: peanut consumption >=600 mg, omalizumab vs placebo
“A total of 79 of the 118 participants who received omalizumab (67%) were able to consume a single dose of at least 600 mg of peanut protein without dose-limiting symptoms during the post-treatment challenge, as compared with 4 of the 59 participants who received placebo (7%) (between-group difference, 60 percentage points; 95% confidence interval [CI], 47 to 70; P<0.001)”
Find in source
Taken as given: The numbers 79, 118, 4, 59 are the event counts and group totals for the primary endpoint.; The test is two-sided Fisher's exact test.; The reported p-value is <0.001, so the computed p should be less than 0.001.
Method: Two-sided Fisher's exact test on 2x2 table (79, 39, 4, 55).
How we recomputed it: pFisher2x2(79, 39, 4, 55, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Key secondary endpoint: cashew consumption >=1000 mg, omalizumab vs placebo
“Cashew | 99 | 28/68 (41) | 1/31 (3) | 38 (19 to 52) | <0.001”
Find in source
Taken as given: The numbers 28, 68, 1, 31 are the event counts and group totals for cashew.; The test is two-sided Fisher's exact test.; The reported p-value is <0.001.
Method: Two-sided Fisher's exact test on 2x2 table (28, 40, 1, 30).
How we recomputed it: pFisher2x2(28, 40, 1, 30, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Key secondary endpoint: egg consumption >=1000 mg, omalizumab vs placebo
“Egg | 71 | 34/51 (67) | 0/20 (0) | 67 (46 to 79) | <0.001”
Find in source
Taken as given: The numbers 34, 51, 0, 20 are the event counts and group totals for egg.; The test is two-sided Fisher's exact test.; The reported p-value is <0.001.
Method: Two-sided Fisher's exact test on 2x2 table (34, 17, 0, 20).
How we recomputed it: pFisher2x2(34, 17, 0, 20, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Key secondary endpoint: milk consumption >=1000 mg, omalizumab vs placebo
“Milk | 62 | 27/41 (66) | 2/21 (10) | 56 (30 to 74) | <0.001”
Find in source
Taken as given: The numbers 27, 41, 2, 21 are the event counts and group totals for milk.; The test is two-sided Fisher's exact test.; The reported p-value is <0.001.
Method: Two-sided Fisher's exact test on 2x2 table (27, 14, 2, 19).
How we recomputed it: pFisher2x2(27, 14, 2, 19, 0)

lowinternal contradiction
The abstract states 'Of the 462 persons who were screened, 180 underwent randomization' but the Results section states 'A total of 435 children and adolescents were screened, of whom 177 underwent randomization'. The discrepancy is explained by the inclusion of adults in the abstract (180 total) vs. pediatric population (177).
“Of the 462 persons who were screened, 180 underwent randomization. The analysis population consisted of the 177 children and adolescents (1 to 17 years of age).”
AbstractFind in source
lowinternal contradiction
The abstract reports '79 of the 118 participants (67%)' for the primary endpoint, but the Results section reports '79 of the 118 participants who received omalizumab (67%)' - consistent. No issue.
“A total of 79 of the 118 participants (67%) receiving omalizumab met the primary end-point criteria”
AbstractFind in source

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

partialReviewers 1, 2
Additional treatment for 24 weeks in the open-label extension appeared to show the durability of this response.
The open-label extension data show that most participants had stable or increased thresholds, but the lack of a control group limits the strength of this claim.
Evidence: In the open-label extension, thresholds for most participants either remained the same or increased (for peanut, 45% unchanged, 34% higher, 21% lower).
“Additional treatment for 24 weeks in the open-label extension trial appeared to show the durability of this response, with most participants showing stable or increased challenge thresholds.”
DiscussionFind in source
supportedReviewers 1, 2
Omalizumab treatment for 16 weeks was superior to placebo in increasing the reaction threshold for peanut and other common food allergens.
The primary and key secondary endpoints all showed statistically significant differences favoring omalizumab, with large effect sizes.
Evidence: Primary endpoint: 67% vs 7% (P<0.001); key secondary endpoints: cashew 41% vs 3%, milk 66% vs 10%, egg 67% vs 0% (all P<0.001).
“In persons as young as 1 year of age with multiple food allergies, omalizumab treatment for 16 weeks was superior to placebo in increasing the reaction threshold for peanut and other common food allergens.”
ConclusionFind in source
supportedReviewers 1, 2
Omalizumab improved the ability to consume multiple foods without adverse effects.
The secondary endpoint data show that a substantial proportion of omalizumab-treated participants could consume multiple foods at various doses.
Evidence: 80% consumed 1044 mg of any one food, 69% consumed 1044 mg of two foods, and 47% consumed 1044 mg of three foods.
“Furthermore, omalizumab improved the ability to consume multiple foods without adverse effects; for example, 80% of the participants were able to consume a cumulative dose of 1044 mg of any one food without adverse effects, 69% were able to consume 1044 mg of two foods, and 47% were able to consume 1044 mg of three foods.”
DiscussionFind in source
supportedReviewer 1
No differences in quality of life were detected during the blinded phase of the trial.
The paper reports no changes in quality of life scores at the end of the first stage, which is a null result reported transparently.
Evidence: No changes were seen in either the caregiver or participant scores at the end of the first stage of the trial as compared with the scores at baseline.
No changes were seen in either the caregiver or participant scores at the end of the first stage of the trial as compared with the scores at baseline.
Resultsreviewer’s wording
supportedReviewer 2
These levels of protection are likely to exceed those that would be needed for the amounts of food that are typically encountered during accidental exposure.
The threshold doses achieved (e.g., 600 mg peanut protein) are higher than typical accidental exposure amounts, supporting the claim.
Evidence: 67% of participants could consume at least 600 mg peanut protein (cumulative 1044 mg, ~4 peanuts).
“These levels of protection are likely to exceed those that would be needed for the amounts of food that are typically encountered during accidental exposure”
DiscussionFind in source
supportedReviewer 2
The trial population is representative of patients with multiple food allergies except for a lower percentage of Hispanic participants.
The paper acknowledges the limitation of underrepresentation of Hispanic participants, which is consistent with the claim.
Evidence: The trial population is representative of patients with multiple food allergies except for a lower percentage of Hispanic participants than in the general population.
The trial population is representative of patients with multiple food allergies except for a lower percentage of Hispanic participants than in the general population.
Resultsreviewer’s wording

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

INADEQUATESurrogate endpoint
The primary efficacy endpoint is the ability to consume a threshold dose of food protein without dose-limiting symptoms during a food challenge, which is a surrogate for protection against accidental exposure. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data showing IgE suppression) nor cite validated evidence linking this surrogate to a hard clinical outcome such as reduced anaphylaxis or improved quality of life. The surrogate is a mechanistic proxy for clinical benefit.
“The primary end point was ingestion of peanut protein in a single dose of 600 mg or more without dose-limiting symptoms.”
Find in source
INADEQUATEEffect size
The primary effect is reported as 67% of omalizumab-treated participants meeting the threshold versus 7% on placebo, but the threshold (600 mg peanut protein) is a surrogate and the clinical meaningfulness is not anchored to a validated minimal clinically important difference or a hard outcome. The paper states the effect 'likely exceed[s] those that would be needed for accidental exposure' but does not provide a validated anchor for clinical significance.
“These levels of protection are likely to exceed those that would be needed for the amounts of food that are typically encountered during accidental exposure”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on food allergy prevalence, the limitations of current treatments, and previous small trials of omalizumab. The rationale for a phase 3 trial is clearly stated. Limitations of prior work (small trials, need for larger evaluation) are addressed by the design of this larger trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

“Omalizumab, a monoclonal antibody that binds to IgE, has shown promise for the treatment of food allergy in numerous small trials.”

Introduction ¶2Find in source

paraphrase[Introduction, paragraph 3]

“Paraphrase: The trial is designed as a phase 3 trial to more fully evaluate safety and efficacy, addressing the limitation of small prior trials.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

“Omalizumab, a monoclonal antibody that binds to IgE, has shown promise for the treatment of food allergy in numerous small trials.”

Introduction ¶1Find in source

“The Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy (OIT) in Food Allergic Children and Adults (OUtMATCH) trial was designed as a phase 3 trial to more fully evaluate the safety and efficacy of omalizumab as a treatment that blocks immune responses irrespective of antigen type for patients as young as 1 year of age who are allergic to multiple foods.”

Introduction ¶3Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed.

Randomization method (2:1 ratio) is stated, though the specific method (e.g., computer-generated) is not detailed. Blinding is described as double-blind. Power analysis is referenced but not fully detailed in the text. Inclusion/exclusion criteria are clearly defined. The analysis population is pre-specified. Outlier handling is addressed through imputation of failure for missing challenges. Controls are appropriate (placebo). Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified endpoints.

Evidence

“Participants underwent randomization, in a 2:1 ratio, to receive omalizumab or placebo”

MethodsFind in source

“OUtMATCH is a double-blind, randomized, placebo-controlled trial”

MethodsFind in source

paraphrase[Methods, Statistical Analysis]

“Additional statistical methods and power analyses are shown in the Supplementary Appendix”

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified endpoints.

Evidence

“Participants underwent randomization, in a 2:1 ratio, to receive omalizumab or placebo”

MethodsFind in source

“OUtMATCH is a double-blind, randomized, placebo-controlled trial”

MethodsFind in source

“Additional statistical methods and power analyses are shown in the , including and .”

Statistical analysisFind in source

Sex, age, and health status (atopic conditions) are reported. Demographics include sex, age, and race/ethnicity (noted as mostly non-Hispanic White). Species/strain and housing are not applicable. Sex justification is not applicable as both sexes are enrolled.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported for the human trial population.

Evidence

“Male sex — no. (%) | 69 (58%) | 31 (53%)”

Table 1Find in source

“asthma, atopic dermatitis, allergic rhinitis, or all three were reported in a majority of the participants”

ResultsFind in source

“the cohort was mostly non-Hispanic and White”

DiscussionFind in source

PASSReviewer 2· 90% conf

Biological variables are adequately reported for a human trial, including sex, age, and demographics.

Evidence

“A total of 56% of the participants were boys”

ResultsFind in source

“the median age of all participants was 7.0 years”

ResultsFind in source

“the cohort was mostly non-Hispanic and White”

LimitationsFind in source

The trial was approved by a named central IRB (Johns Hopkins University). Informed consent is implied by the trial's conduct and the statement that participants were enrolled; however, the specific consent process is not detailed in the text. Regulatory compliance is stated via the investigational new drug application and monitoring by a data and safety monitoring board.

Sub-criteria

iacuc statementN/A

informed consentINADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately documented.

Evidence

“The trial was approved by a central institutional review board at Johns Hopkins University”

MethodsFind in source

“conducted under an investigational new drug application (number 140847), and monitored by an independent data and safety monitoring board”

MethodsFind in source

absence[Methods]

Informed consent is not explicitly described in the text.

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported with a named IRB and informed consent implied.

Evidence

“The trial was approved by a central institutional review board at Johns Hopkins University”

MethodsFind in source

absence[Methods]

Informed consent is not explicitly described in main text.

“conducted under an investigational new drug application (number 140847)”

MethodsFind in source

Omalizumab is identified as a monoclonal anti-IgE antibody, with dosing based on weight and IgE levels. The manufacturer (Genentech/Novartis) is mentioned. Skin-prick test devices and ImmunoCAP are identified with vendors. Software tools are not detailed but are not bespoke. Antibodies, cell lines, mycoplasma, and organisms are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (omalizumab) is adequately identified, and other resources are appropriately described.

Evidence

“omalizumab, a monoclonal anti-IgE antibody”

AbstractFind in source

paraphrase[Table 1 footnote]

“Skin‑prick testing was performed with the use of the Greer Pick device and extracts (Stallergenes Greer, Lenoir, NC)... Allergen‑specific IgE levels were measured by means of ImmunoCAP (Thermo Fisher Scientific, Waltham, MA).”

absence[Methods, Statistical Analysis]

Statistical software is not identified in the text.

PASSReviewer 2· 90% conf

The investigational product (omalizumab) is adequately identified, and other resources are appropriately identified.

Evidence

“Genentech and Novartis provided the investigational product”

MethodsFind in source

“Skin‑prick testing was performed with the use of the Greer Pick device and extracts (Stallergenes Greer, Lenoir, NC).”

Table 1Find in source

absence[Methods, Statistical Analysis]

Statistical software is not identified in main text.

Fisher's exact test is named for primary and key secondary endpoints. Exact p-values are reported (P<0.001). Effect sizes with confidence intervals are reported. Statistical software is not identified in main text. Data presentation includes per-group n and percentages. Mathematical plausibility checks are not applicable due to large N and continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals for key endpoints.

Evidence

“we used a two-sided Fisher’s exact test to compare the two groups”

Statistical analysisFind in source

paraphrase[Results, Efficacy]

“P<0.001”

“between-group difference, 60 percentage points; 95% confidence interval [CI], 47 to 70”

ResultsFind in source

PASSReviewer 2· 95% conf

Statistical analysis is rigorous with named tests, exact p-values, and appropriate handling of multiplicity.

Evidence

“we used a two-sided Fisher’s exact test to compare the two groups”

Statistical analysisFind in source

paraphrase[Results, Efficacy]

“P<0.001”

“between-group difference, 60 percentage points; 95% confidence interval [CI], 47 to 70”

ResultsFind in source

The paper states that a data sharing statement is available with the full text, but the specific mechanism is not described in the text. No repository deposit or accession numbers are provided. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement is mentioned but not detailed; no repository or code is provided.

Evidence

“A data sharing statement provided by the authors is available with the full text of this article at NEJM.org”

FundingFind in source

absence[Data Availability]

No repository deposit is mentioned.

WARNReviewer 2· 80% conf

A data sharing statement is mentioned but not detailed in the main text; no repository or accession numbers are provided.

Evidence

“A data sharing statement provided by the authors is available with the full text of this article at NEJM.org”

Supplementary materialFind in source

absence[Supplementary Material]

No repository deposit is mentioned.

absence[Full text]

No code sharing is mentioned.

The trial is registered (NCT03881696). Reporting guideline (CONSORT) is not explicitly mentioned but the paper follows clinical trial reporting standards. All outcomes are reported, including negative results (quality of life). Limitations are discussed. Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with complete methods, trial registration, and discussion of limitations.

Evidence

paraphrase[Abstract]

“ClinicalTrials.gov number, NCT03881696”

“The trial also has limitations. Only three adults were included, and the cohort was mostly non-Hispanic and White”

DiscussionFind in source

paraphrase[Funding section]

“Supported by the National Institute of Allergy and Infectious Diseases and the National Center for Advancing Translational Sciences... Disclosure forms provided by the authors are available”

PASSReviewer 2· 95% conf

Reporting is transparent with trial registration, funding, and limitations discussed.

Evidence

“ClinicalTrials.gov (http://clinicaltrials.gov) number, NCT03881696”

AbstractFind in source

“The trial also has limitations. Only three adults were included, and the cohort was mostly non-Hispanic and White”

DiscussionFind in source

“Supported by the National Institute of Allergy and Infectious Diseases and the National Center for Advancing Translational Sciences”

Supplementary materialFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT03881696

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 30 references by DOI: 30 verified.

Every extracted reference resolved against Crossref/OpenAlex with no retraction flags.

1 data/code link checked; 1 live.

datahttps://clinicaltrials.gov/ct2/show/NCT03881696LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, punctuation.

MINORconsistencyAbstract
“National Institutes of Allergy and Infectious Diseases”
→ Change to 'National Institute of Allergy and Infectious Diseases'
Inconsistent naming of the institute.
MINORclarityMethods, Trial Design and Oversight
“The trial methods have been published, and the protocol and statistical analysis plan are available with the full text of this article at NEJM.org”
→ Consider adding a direct link or reference to the published methods.
Clarity improvement.
MINORconsistencyAbstract
“National Institutes of Allergy and Infectious Diseases”
→ Change to 'National Institute of Allergy and Infectious Diseases' for consistency with the rest of the text.
Inconsistent naming of the institute.
MINORclarityMethods, Statistical Analysis
“Additional statistical methods and power analyses are shown in the , including and .”
→ Replace with specific references to supplementary sections or figures.
Placeholder text not resolved.
MINORpunctuationResults, Participants
“A total of 435 children and adolescents were screened, of whom 177 underwent randomization from September 2019 through November 2022 ();”
→ Insert a figure reference after the parentheses.
Missing figure citation.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and methodologically sound. An informed reader should weigh the minor reporting gaps (data sharing mechanism, statistical software, demographic detail) as limitations but they do not undermine the validity of the findings. No erratum or correction appears warranted based on the checks performed.

1.
HIGHdata code
In the Data Availability section, specify the concrete data sharing mechanism (e.g., managed-access platform like Vivli or a data-access committee) with conditions and timeframe.
The current statement is vague and does not meet transparency expectations for a clinical trial.
2.
HIGHstatistics
In the Methods, Statistical Analysis section, identify the statistical software used (e.g., SAS version) for the analyses.
Software identification is a standard reporting requirement for reproducibility.
3.
MEDIUMreporting
In the Methods, Randomization and Enrollment section, specify the randomization method (e.g., computer-generated random sequence) and the randomization unit.
The current description only states the ratio, not the method, which is a minor reporting gap.
4.
MEDIUMreporting
In the Methods, Statistical Analysis section, provide details of the power analysis (assumed effect size, alpha, power) or reference the supplement more clearly.
Power analysis details are currently only referenced, not described, which limits assessment of study design.
5.
MEDIUMethics
In the Methods, Trial Design and Oversight section, explicitly state that informed consent was obtained from participants or their guardians and describe the consent process.
Informed consent is not explicitly described in the main text, which is a reporting gap for an interventional trial.
6.
MEDIUMreporting
In the Methods or a separate section, mention adherence to CONSORT guidelines or provide a CONSORT checklist.
Reporting guideline adherence is not explicitly stated, though the paper follows standard reporting.
7.
MEDIUMreporting
In the Results, Participants section, provide a more detailed demographic breakdown, including race/ethnicity, to address generalizability concerns.
The cohort is described as mostly non-Hispanic White, but a full breakdown would improve transparency.
8.
LOWcopyedit
In the Abstract, correct 'National Institutes of Allergy and Infectious Diseases' to 'National Institute of Allergy and Infectious Diseases' for consistency.
Inconsistent naming of the institute is a minor copyedit issue.
9.
LOWcopyedit
In the Methods, Statistical Analysis, replace the placeholder text 'shown in the , including and .' with specific references to supplementary sections or figures.
Placeholder text is unresolved and should be fixed for clarity.
10.
LOWcopyedit
In the Results, Participants, insert the missing figure reference after the parentheses in the sentence about screening and randomization.
Missing figure citation is a minor copyedit issue.
11.
LOWcopyedit
In the Methods, Trial Design and Oversight, consider adding a direct link or reference to the published methods for clarity.
Clarity improvement for readers seeking the full protocol.

Full text (34,716 chars)Analyzed: Aug 16, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Omalizumab for the Treatment of Multiple Food Allergies.

DOI

10.1056/NEJMoa2312382

Record issued

2026-08-16

Engine

7.39.0

Exported

2026-09-20